Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Recurrent Gliomas
NCT01986348Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Mar 2014
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of selinexor in glioblastoma (GBM), sponsored by Karyopharm Therapeutics Inc.. Started Mar 2014; status: terminated.
02
Drugs
selinexor
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01986348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01986348.